Cyanide, Peroxide and Nitric Oxide Formation in Solutions of Hydroxyurea Causes Cellular Toxicity and May Contribute to Its Therapeutic Potency

Journal of Molecular Biology

Volumn 390, Issue 5, 2009, Pages 845-862

  Kuong, Kawai J ^a   Kuzminov, Andrei ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

hydrogen cyanide; hydrogen peroxide; hydroxyurea; nitric oxide; thymineless death

Indexed keywords

BACTERIAL DNA; HYDROGEN CYANIDE; HYDROGEN PEROXIDE; HYDROXYUREA; NITRIC OXIDE;

ARTICLE; BACTERIAL CELL; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG POTENCY; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL;

ESCHERICHIA COLI; EUKARYOTA;

EID: 67649861902     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.05.038     Document Type: Article

References (109)

1. Navarra P., and Preziosi P. Hydroxyurea: new insights on an old drug. Crit. Rev. Oncol. Hematol. 29 (1999) 249-255
2. Elford H.L. Effect of hydroxyurea on ribonucleotide reductase. Biochem. Biophys. Res. Commun. 33 (1968) 129-135
3. Krakoff I.H., Brown N.C., and Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 28 (1968) 1559-1565
4. Reichard P., and Ehrenberg A. Ribonucleotide reductase-a radical enzyme. Science 221 (1983) 514-519
5. Sinha N.K., and Snustad D.P. Mechanism of inhibition of deoxyribonucleic acid synthesis in Escherichia coli by hydroxyurea. J. Bacteriol. 112 (1972) 1321-1334
6. Yarbro J.W. Mechanism of action of hydroxyurea. Semin. Oncol. 19 (1992) 1-10
7. Young C.W., and Hodas S. Hydroxyurea: inhibitory effect on DNA metabolism. Science 146 (1964) 1172-1174
8. Young C.W., Schochetman G., Hodas S., and Balis M.E. Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships. Cancer Res. 27 (1967) 535-540
9. Rosenkranz H.S., and Carr H.S. Studies with hydroxyurea. II. Prolonged exposure of Escherichia coli to hydroxyurea. J. Bacteriol. 92 (1966) 178-185
10. Rosenkranz H.S., Garro A.J., Levy J.A., and Carr H.S. Studies with hydroxyurea. I. The reversible inhibition of bacterial DNA synthesis and the effect of hydroxyurea on the bactericidal action of streptomycin. Biochim. Biophys. Acta 114 (1966) 501-515
11. Bradley M.O., Kohn K.W., Sharkey N.A., and Ewig R.A. Differential cytotoxicity between transformed and normal human cells with combinations of aminonucleoside and hydroxyurea. Cancer Res. 37 (1977) 2126-2131
12. Farber E., and Baserga R. Differential effects of hydroxyurea on survival of proliferating cells in vivo. Cancer Res. 29 (1969) 136-139
13. Grdina D.J., Sigdestad C.P., and Peters L.J. Phase-specific cytotoxicity in vivo of hydroxyurea on murine fibrosarcoma cells synchronized by centrifugal elutriation. Br. J. Cancer 39 (1979) 152-158
14. Sawicki S.G., and Godman G.C. On the differential cytotoxicity of actinomycin D. J. Cell Biol. 50 (1971) 746-761
15. Sinclair W.K. Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle. Science 150 (1965) 1729-1731
16. Rice L., and Baker K.R. Current management of the myeloproliferative disorders: a case-based review. Arch. Pathol. Lab. Med. 130 (2006) 1151-1156
17. Lanzkron S., Strouse J.J., Wilson R., Beach M.C., Haywood C., Park H., et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann. Intern. Med. 148 (2008) 939-955
18. Newton H.B., Scott S.R., and Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br. J. Neurosurg. 18 (2004) 495-499
19. Lori F., Foli A., Groff A., Lova L., Whitman L., Bakare N., et al. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. AIDS 19 (2005) 1173-1181
20. Schilsky R.L. Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Semin. Oncol. 19 (1992) 2-7
21. Frame D. Chronic myeloid leukemia: standard treatment options. Am. J. Health-Syst. Pharm. 63 (2006) S10-S14
22. Fishbein W.N., and Carbone P.P. Hydroxyurea: mechanism of action. Science 142 (1963) 1069-1070
23. Jiang J., Jordan S.J., Barr D.P., Gunther M.R., Maeda H., and Mason R.P. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol. Pharmacol. 52 (1997) 1081-1086
24. King S.B. N-Hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors. Curr. Top. Med. Chem. 5 (2005) 665-673
25. Rosenkranz H.S. Some biological effects of carbamoyloxyurea, an oxidation product of hydroxyurea. J. Bacteriol. 102 (1970) 20-23
26. Sakano K., Oikawa S., Hasegawa K., and Kawanishi S. Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn. J. Cancer Res. 92 (2001) 1166-1174
27. Ahmad S.I., Kirk S.H., and Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu. Rev. Microbiol. 52 (1998) 591-625
28. Morganroth P.A., and Hanawalt P.C. Role of DNA replication and repair in thymineless death in Escherichia coli. J. Bacteriol. 188 (2006) 5286-5288
29. Fishbein W.N., Winter T.S., and Davidson J.D. Urease catalysis. I. Stoichiometry, specificity and kinetics of a second substrate: hydroxyurea. J. Biol. Chem. 240 (1965) 2402-2406
30. Heeney M.M., Whorton M.R., Howard T.A., Johnson C.A., and Ware R.E. Chemical and functional analysis of hydroxyurea oral solutions. J. Pediatr. Hematol. Oncol. 26 (2004) 179-184
31. King S.B. Nitric oxide production from hydroxyurea. Free Radical Biol. Med. 37 (2004) 737-744
32. Shimada K., Shibata Y., and Takagi Y. Bacteriocidal action of hydroxyurea on Escherichia coli K12 recA. Jpn. J. Microbiol. 19 (1975) 72-74
33. El-Yazigi A., and Al-Rawithi S. Analysis of hydroxyurea in capsules and aqueous solution and stability study with capillary gas chromatography and thermionic (N-P) specific detection. Pharm. Res. 9 (1992) 115-118
34. Jacobs S.J., and Rosenkranz H.S. Detection of a reactive intermediate in the reaction between DNA and hydroxyurea. Cancer Res. 30 (1970) 1084-1094
35. Lunghi A., Aloni C., Gigante L., Mazzei N., and Cardillo P. Hydroxyurea explosion: a thermoanalytical and calorimetric study. J. Loss Prev. Process Ind. 15 (2002) 489-495
36. Drlica K., Engle E.C., and Manes S.H. DNA gyrase on the bacterial chromosome: possibility of two levels of action. Proc. Natl Acad. Sci. USA 77 (1980) 6879-6883
37. Kuzminov A., Schabtach E., and Stahl F.W. c-sites in combination with RecA protein increase the survival of linear DNA in E. coli by inactivating ExoV activity of RecBCD nuclease. EMBO J. 13 (1994) 2764-2776
38. Kouzminova E.A., and Kuzminov A. Fragmentation of replicating chromosomes triggered by uracil in DNA. J. Mol. Biol. 355 (2006) 20-33
39. Kouzminova E.A., Rotman E., Macomber L., Zhang J., and Kuzminov A. RecA-dependent mutants in E. coli reveal strategies to avoid replication fork failure. Proc. Natl Acad. Sci. USA 101 (2004) 16262-16267
40. Hill W.E., and Fangman W.L. Single-strand breaks in deoxyribonucleic acid and viability loss during deoxyribonucleic acid synthesis inhibition in Escherichia coli. J. Bacteriol. 116 (1973) 1329-1335
41. Rosenkranz H.S., Jacobs S.J., and Carr H.S. Studies with hydroxyurea, VIII. The deoxyribonucleic acid of hydroxyurea-treated cells. Biochim. Biophys. Acta 161 (1968) 428-441
42. Kuzminov A., and Stahl F.W. Overview of homologous recombination and repair machines. In: Higgins N.P. (Ed). The Bacterial Chromosome (2005), ASM Press, Washington, DC 349-367
43. Beam C.E., Saveson C.J., and Lovett S.T. Role for radA/sms in recombination intermediate processing in Escherichia coli. J. Bacteriol. 184 (2002) 6836-6844
44. Guarino E., Salguero I., Jiménez-Sánchez A., and Guzmán E.C. Double-strand break generation under deoxyribonucleotide starvation in Escherichia coli. J. Bacteriol. 189 (2007) 5782-5786
45. Friedberg E.C., Walker G.C., Siede W., Wood R.D., Schultz R.A., and Ellenberger T. DNA Repair and Mutagenesis (2006), ASM Press, Washington, DC
46. Cunningham R.P., Saporito S.M., Spitzer S.G., and Weiss B. Endonuclease IV (nfo) mutant of Escherichia coli. J. Bacteriol. 168 (1986) 1120-1127
47. Stevanin T.M., Ioannidis N., Mills C.E., Kim S.O., Hughes M.N., and Poole R.K. Flavohemoglobin Hmp affords inducible protection for Escherichia coli respiration, catalyzed by cytochromes bo′ or bd, from nitric oxide. J. Biol. Chem. 275 (2000) 35868-35875
48. Yu H., Sato E.F., Nagata K., Nishikawa M., Kashiba M., Arakawa T., et al. Oxygen-dependent regulation of the respiration and growth of Escherichia coli by nitric oxide. FEBS Lett. 409 (1997) 161-165
49. Dunbar K.R., and Heintz R.A. Chemistry of transition metal cyanide compounds: modern perspectives. Prog. Inorg. Chem. 45 (1997) 283-391
50. Kujundzic N., Nigovic B., and Sankovic K. Reaction of hydroxyurea with iron(III): products and the stoichiometry of the redox reaction. Z. Anorg. Allg. Chem. 630 (2004) 2749-2753
51. Miller M.J. Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogues. Chem. Rev. 89 (1989) 1563-1579
52. Nakayama H., and Hanawalt P.C. Sedimentation analysis of deoxyribonucleic acid from thymine-starved Escherichia coli. J. Bacteriol. 121 (1975) 537-547
53. Brunelli L., Crow J.P., and Beckman J.S. The comparative toxicity of nitric oxide and peroxynitrite to Escherichia coli. Arch. Biochem. Biophys. 316 (1995) 327-334
54. Imlay J.A., Chin S.M., and Linn S. Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro. Science 240 (1988) 640-642
55. Pacelli R., Wink D.A., Cook J.A., Krishna M.C., DeGraff W., Friedman N., et al. Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli. J. Exp. Med. 182 (1995) 1469-1479
56. Woodmansee A.N., and Imlay J.A. Reduced flavins promote oxidative DNA damage in non-respiring Escherichia coli by delivering electrons to intracellular free iron. J. Biol. Chem. 277 (2002) 34055-34066
57. Woodmansee A.N., and Imlay J.A. A mechanism by which nitric oxide accelerates the rate of oxidative DNA damage in Escherichia coli. Mol. Microbiol. 49 (2003) 11-22
58. Nordlund P., and Reichard P. Ribonucleotide reductases. Annu. Rev. Biochem. 75 (2006) 681-706
59. Karlsson M., Sahlin M., and Sjöberg B.M. Escherichia coli ribonucleotide reductase. Radical susceptibility to hydroxyurea is dependent on the regulatory state of the enzyme. J. Biol. Chem. 267 (1992) 12622-12626
60. Sneeden J.L., and Loeb L.A. Mutations in the R2 subunit of ribonucleotide reductase that confer resistance to hydroxyurea. J. Biol. Chem. 279 (2004) 40723-40728
61. Spek E.J., Wright T.L., Stitt M.S., Taghizadeh N.R., Tannenbaum S.R., Marinus M.G., and Engelward B.P. Recombinational repair is critical for survival of Escherichia coli exposed to nitric oxide. J. Bacteriol. 183 (2001) 131-138
62. Sutera V.A.J., and Lovett S.T. The role of replication initiation control in promoting survival of replication fork damage. Mol. Microbiol. 60 (2006) 229-239
63. Michel B., Grompone G., Florès M.J., and Bidnenko V. Multiple pathways process stalled replication forks. Proc. Natl Acad. Sci. USA 101 (2004) 12783-12788
64. Kuzminov A. Instability of inhibited replication forks in E. coli. BioEssays 17 (1995) 733-741
65. Ishii Y., and Kondo S. Comparative analysis of deletion and base-change mutabilities of Escherichia coli B strains differing in DNA repair capacity (wild-type, uvrA-, polA-, recA-) by various mutagens. Mutat. Res. 27 (1975) 27-44
66. Blumenreich M.S., Kellihan M.J., Joseph U.G., Lalley K.A., Sherrill E.J., Sullivan D.M., et al. Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial. Cancer 71 (1993) 2828-2832
67. Kaubisch A., Kaleya R., Haynes H., Rozenblit A., and Wadler S. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. Cancer Chemother. Pharmacol. 53 (2004) 337-340
68. Newman E.M., Carroll M., Akman S.A., Chow W., Coluzzi P., Hamasaki V., et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 39 (1997) 254-258
69. Smith D.C., Vaughan W.P., Gwilt P.R., and Trump D.L. A phase I trial of high-dose continuous-infusion hydroxyurea. Cancer Chemother. Pharmacol. 33 (1993) 139-143
70. Swinnen L.J., Rankin C., Carraway H., Albain K.S., Townsend J.J., Budd G.T., et al. A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J. Neuro-Oncol. 86 (2008) 353-358
71. Hampton M.B., Kettle A.J., and Winterbourn C.C. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92 (1998) 3007-3017
72. Vazquez-Torres A., and Fang F.C. Oxygen-dependent anti-Salmonella activity of macrophages. Trends Microbiol. 9 (2001) 29-33
73. Graham G.G., Whitehouse M.W., and Bushell G.R. Aurocyanide, dicyano-aurate (I), a pharmacologically active metabolite of medicinal gold complexes. Inflammopharmacology 16 (2008) 126-132
74. But P.G., Muraviev R.A., Fomina V.A., and Rogovin V.V. Antimicrobial activity of mieloperoxidase from neutrophilic peroxisome. Biol. Bull. 29 (2002) 212-215
75. Stelmaszynska T. Formation of HCN by human phagocytosing neutrophils-1. Chlorination of Staphylococcus epidermidis as a source of HCN. Int. J. Biochem. 17 (1985) 373-379
76. Stelmaszynska T. Formation of HCN and its chlorination to ClCN by stimulated human neutrophils-2. Oxidation of thiocyanate as a source of HCN. Int. J. Biochem. 18 (1986) 1107-1114
77. 2-Cl- system. Biochim. Biophys. Acta 567 (1979) 309-314
78. Furtmüller P.G., Burner U., and Obinger C. Reaction of myeloperoxidase compound I with chloride, bromide, iodide, and thiocyanate. Biochemistry 37 (1998) 17923-17930
79. Thomas E.L., and Fishman M. Oxidation of chloride and thiocyanate by isolated leukocytes. J. Biol. Chem. 261 (1986) 9694-9702
80. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin. Hematol. 34 (1997) 15-21
81. Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv. Pediatr. 37 (1990) 1-31
82. Faust, R. A. (1994). Toxicity Summary for Cyanide, Oak Ridge Reservation Environmental Restoration Program.
83. Petrova, F. & Fishbein, L. (2004). Hydrogen cyanide and cyanides: human health aspects. Concise International Chemical Assessment Document 61, World Health Organization.
84. Torrance E.G., and Schnabel T.G. Potassium sulphocyanate: a note on its use for the painful crises in sickle cell anemia. Ann. Intern. Med. 6 (1932) 782-788
85. Malomo S.O., and Oyewole O.I. Cations content and membrane properties of human sickle blood incubated with hydroxyurea, tellurite and thiocyanate. Egypt. J. Biochem. Mol. Biol. 26 (2008) 117-125
86. Oyewole O.I., Malomo S.O., and Adebayo J.O. Comparative studies on antisickling properties of thiocyanate, tellurite and hydroxyurea. Pakistan J. Med. Sci. 24 (2008) 18-22
87. Agbai O. Anti-sickling effect of dietary thiocyanate in prophylactic control of sickling cell anemia. J. Natl Med. Assoc. 78 (1986) 1053-1056
88. Houston R.G. Sickle cell anemia and dietary precursors of cyanate. Am. J. Clin. Nutr. 26 (1973) 1261-1264
89. Houston R.G. Letter: dietary nitriloside and sickle cell anemia in Africa. Am. J. Clin. Nutr. 27 (1974) 766-769
90. Lambotte C. Letter: sickle cell anemia and dietary precursors of cyanate. Am. J. Clin. Nutr. 27 (1974) 765-766
91. Cerami A., Allen T.A., Graziano J.H., DeFuria F.G., Manning J.M., and Gillette P.N. Pharmacology of cyanate. I. General effects on experimental animals. J. Pharmacol. Exp. Ther. 185 (1973) 653-666
92. Gillette P.N., Manning J.M., and Cerami A. Increased survival of sickle-cell erythrocytes after treatment in vitro with sodium cyanate. Proc. Natl Acad. Sci. USA 68 (1971) 2791-2793
93. Cerami A., and Manning J.M. Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro. Proc. Natl Acad. Sci. USA 68 (1971) 1180-1183
94. Jackson L.C., Oseguera M., Medrano S., and Kim Y.L. Carbamylation of hemoglobin in vivo with chronic sublethal dietary cyanide: implications for hemoglobin S. Biochem. Med. Metab. Biol. 39 (1988) 64-68
95. Bachmann B.J. Derivations and genotypes of some mutant derivatives of Escherichia coli K-12. In: Neidhardt F.C. (Ed). Escherichia coli and Salmonella typhimurium. Cellular and Molecular Biology (1987), American Society for Microbiology, Washington, DC 1190-1219
96. Czonka L.N., and Clark A.J. Deletions generated by the transposon Tn10 in the srl-recA region of the Escherichia coli K-12 chromosome. Genetics 93 (1979) 321-343
97. Shi I.Y., Stansbury J., and Kuzminov A. Defect in acetyl-CoA↔acetate pathway poisons recombinational repair-deficient mutants of Escherichia coli. J. Bacteriol. 187 (2005) 1266-1275
98. Miranda A., and Kuzminov A. Chromosomal lesion suppression and removal in Escherichia coli via linear DNA degradation. Genetics 163 (2003) 1255-1271
99. Datsenko K.A., and Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl Acad. Sci. USA 97 (2000) 6640-6645
100. Miller J.H. Experiments in Molecular Genetics (1972), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
101. Zalkin H., and Nygaard P. Biosynthesis of purine nucleotides. In: Neidhardt F.C. (Ed). Escherichia coli and Salmonella. Cellular and Molecular Biology (1996), ASM Press, Washington, DC 561-579
102. Hiraga S., Igarashi K., and Yura T. A deoxythymidine kinase-deficient mutant of Escherichia coli, I. Isolation and some properties. Biochim. Biophys. Acta 145 (1967) 41-51
103. Neidhardt F.C., Bloch P.L., and Smith D.F. Culture medium for enterobacteria. J. Bacteriol. 119 (1974) 736-747
104. Rotman E., and Kuzminov A. The mutT defect does not elevate chromosomal fragmentation in Escherichia coli because of the surprisingly low levels of MutM/MutY-recognized DNA modifications. J. Bacteriol. 189 (2007) 6976-6988
105. Rosche W.A., and Foster P.L. Determining mutation rates in bacterial populations. Methods 20 (2000) 4-17
106. Seaver L.C., and Imlay J.A. Alkyl hydroperoxide reductase is the primary scavenger of endogenous hydrogen peroxide in Escherichia coli. J. Bacteriol. 183 (2001) 7173-7181
107. Imlay J.A., and Fridovich I. Assay of metabolic superoxide production in Escherichia coli. J. Biol. Chem. 266 (1991) 6957-6965
108. Korshunov S., and Imlay J.A. Detection and quantification of superoxide formed within the periplasm of Escherichia coli. J. Bacteriol. 188 (2006) 6326-6334
109. Gut I.M., Prouty A.M., Ballard J.D., van der Donk W.A., and Blanke S.R. Inhibition of Bacillus anthracis spore outgrowth by nisin. Antimicrob. Agents Chemother. 52 (2008) 4281-4288